RecruitingPhase 2NCT06981767

Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus

Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus : A Randomized Clinical Trial


Sponsor

Cairo University

Enrollment

42 participants

Start Date

Feb 18, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Bromelain, an enzyme extract derived from pineapples, has shown promise due to its anti-inflammatory and wound-healing properties. However, its efficacy in treating oral mucosal ulcers remains unexplored. This study aims to provide clinical evidence on the efficacy of bromelain for managing OLP, potentially offering a safer and more effective treatment option.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 0.1% topical triamcinolone acetonide, Combination of Topical Bromelain and Triamcinolone Acetonide in Orabase, and others for people with oral lichen planus. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTTopical Bromelain

A natural enzyme-based formulation derived from pineapple, bromelain in orabase is being investigated for its anti-inflammatory and wound-healing properties. As a non-steroidal alternative, it offers a potentially safer treatment option with minimal side effects.

DRUG0.1% topical triamcinolone acetonide

A corticosteroid-based standard treatment for OLP, triamcinolone acetonide in orabase is used for its strong anti-inflammatory and immunosuppressive effects. It serves as the conventional treatment versus novel therapy in this study

COMBINATION_PRODUCTCombination of Topical Bromelain and Triamcinolone Acetonide in Orabase

This novel formulation combines the enzymatic, healing properties of bromelain with the anti-inflammatory property of triamcinolone. It is designed to provide enhanced therapeutic effects through synergistic action, potentially reducing the required corticosteroid dose while improving clinical outcomes.


Locations(1)

Cairo University

Cairo, Cairo Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06981767


Related Trials